Table 4 Odds ratios for non-steroidal anti-inflammatory drug (NSAID) use stratified on the manganese superoxide dismutase (MnSOD) genotype (multiplicative scale) and joint effects (additive scale) (phase 2 invasive and CIS studies only)
Val/Val or Val/Ala MnSOD genotype | Ala/Ala MnSOD genotype | ||||
|---|---|---|---|---|---|
Use of NSAIDs | Cases/controls | Odds ratio (95% CI) a | Cases/controls | Odds ratio (95% CI) a | ICR (95% CI) |
Multiplicative scale | |||||
Never | 105/48 | Referent | 19/16 | Referent | |
Occasional | 511/420 | 0.6 (0.4–0.8) | 142/127 | 0.8 (0.4–1.9) | |
Short term | 148/141 | 0.4 (0.3–0.7) | 43/36 | 0.9 (0.4–2.4) | |
Long term | 218/200 | 0.4 (0.3–0.7) | 58/58 | 0.9 (0.4–2.1) | |
Additive scale | |||||
Never | 105/48 | Referent | 19/16 | 0.5 (0.2–1.3) | |
Occasional | 511/420 | 0.5 (0.4–0.8) | 142/127 | 0.5 (0.3–0.7) | 0.4 (-0.1, 0.9) |
Short term | 148/141 | 0.4 (0.3–0.7) | 43/36 | 0.5 (0.3–1.0) | 0.5 (-0.1, 1.1) |
Long term | 218/200 | 0.4 (0.3–0.7) | 58/58 | 0.4 (0.2–0.7) | 0.4 (-0.1, 0.9) |